Skip to content

Squalene for COVID-19 treatment

Evaluation the Efficacy of Sublingual Squalene for Treatment of COVID-19

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200927048848N3
Enrollment
200
Registered
2021-10-10
Start date
2021-09-23
Completion date
Unknown
Last updated
2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Standard treatment + sublingual drop containing squalene, 15 drops for the first day of admission and then 10 drops a day for 4 days. Intervention 2: standard treatment: Since the effe

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient with definite COVID-19 confirmed by molecular or imaging methods in which the oxygen saturation level is less than 93% (SPO2 <93%) and requires respiratory support including oxygen therapy. Patient with definite COVID-19 confirmed by molecular or imaging methods with hypotension (systolic pressure less than 90) Patient with definite COVID-19 confirmed by molecular or imaging methods with Persistence of dehydration and oral intolerance after outpatient supportive care Patient with definite COVID-19 confirmed by molecular or imaging methods who are considered as high risk patient regardless of the clinical symptoms based on the underlying disease, clinical condition, and paraclinical findings. (Uncontrolled high blood pressure, uncontrolled diabetes, obesity, etc.)

Exclusion criteria

Exclusion criteria: History of myocardial ischemia, heart failure and advanced COPD Dissatisfaction of the patient or the patient's companion Any mental disability that prevents effective communication Existence of any physical disability that prevents one from performing daily activities independently. (Physical disability leads to disability before COVID-19 infection) History of alcohol or drug abuse Possibility of pregnancy and lactation

Design outcomes

Primary

MeasureTime frame
Fever. Timepoint: Daily for 7days. Method of measurement: thermometer.;SPO2. Timepoint: daily for 7 days if hospitalization continued. Method of measurement: Pulse oxymeter.;Respiratory rate. Timepoint: daily for 7 days. Method of measurement: respiration in one minute.;Food tolerance. Timepoint: daily for 7 days. Method of measurement: physician judgment.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahmoud Ebrahimi

Mashhad University of Medical Sciences

EbrahimiMH@mums.ac.ir38002000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026